Avinger increases focus on coronary development, reduces operating costs of peripheral business

Redwood city, ca / accesswire / june 5, 2024 / avinger, inc. (nasdaq:avgr), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced that it will increase focus on its coronary artery disease program, where it is developing an innovative new image-guided therapeutic system to address unmet coronary market needs, while reducing the operating costs of its peripheral artery disease business. as part of this strategic prioritization, avinger has reduced headcount dedicated to its peripheral business by 33%, which is expected to provide significant cost savings in the second half of 2024.
AVGR Ratings Summary
AVGR Quant Ranking